[PDF] Top 20 Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis
Has 10000 "Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis" found on our website. Below are the top 20 most common "Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis".
Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis
... measured circulating endothelial precursor cells (EPCs), activated circulating endothelial cells (aCECs), and mature circulating endothelial cells (mCECs) ... See full document
6
Gold nanoparticles for nanotheranostics in leukemia – Addressing Chronic Myeloid Leukemia
... particularly leukemia, show their potential as targets of smart nanomaterials and how much these diseases would benefit from a more personalized approach than current diagnostics and treatment ...foremost, ... See full document
220
Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.
... of circulating Arg1, we also investigated whether the serum from patients at diagnosis has immunoinhibitory ...PMNs in CML patients. In fact, even if Gr-MDSCs and PMNs are considered ... See full document
10
ANALYSIS OF mRNA TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA PATIENTS
... b3 in the evolution of CML (Mills et ...of circulating blast cells, and high leuko- cyte counts (Zaccaria et ...spleen are correlated with a bad prognosis, whereas the opposite is ... See full document
6
An uneventful pregnancy and delivery in a patient with chronic myeloid leukemia
... Chronic myeloid leukemia (CML) is a clonal stem cell disorder characterized by increased proliferation of myeloid elements at all stages of ...of myeloid cells showing ... See full document
2
Chronic myeloid leukemia (CML): prognostic factors and survival analysis
... There were 25 (55.6 percent) m ales and 20 (44.4 percent) fem ales. The m edian age was 42 (ranging from 15-77). There were 25 (55.6 percent) white patients, 18 (40.0 percent) were black, and 2 (4.4 percent) were Asian. ... See full document
8
Philadelphia-negative chronic myeloproliferative neoplasms
... millennium. In 2001, the World Health Organization (WHO) defined the classification of this group of diseases and in 2008 they were renamed myeloproliferative neoplasms based on morphological, cytogenetic ... See full document
10
Increased Circulating Cathepsin K in Patients with Chronic Heart Failure.
... Continuous variables are expressed as mean 6 SD or as median and interquartile range for non- parametric variables. Categoric variables were compared with the Pearson chi-square test or the Fisher exact test. ... See full document
11
Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
... [68]. In CML, BCR-ABL triggers tyrosine phosphorylation and hence stabilization and activation of b- catenin [39], which enhances the self-renewal and leukemic potential of CML stem/progenitors cells ... See full document
16
Rev. Bras. Hematol. Hemoter. vol.35 número2
... T cells in a dose-dependent manner. Azacitidine-treated T cells produced signiicantly lower amounts of pro-inlammatory cytokines, tumor necrosis factor (TNF)-α and interferon (IFN)-γ compared with ... See full document
8
J. Braz. Chem. Soc. vol.21 número12
... assessed in the present study are capable to cleave plasmid DNA under deined pH, temperature and time ...inhibited in the presence of free hydroxyl scavengers and anaerobic atmosphere conditions, the ... See full document
14
Rev. Bras. Hematol. Hemoter. vol.39 número2
... expressed lambda chain. Cytogenetic studies of PB for tri- somy 12, del11q23, BCR/ABL1 fusion gene, del17p13.1 (p53) and del13q14.3 molecular abnormalities on fluorescence-activated cell sorting purified CLL-like ... See full document
3
Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia.
... miRNAs are known to play crucial roles as oncogenes or tumor suppressors, and their deregulation is involved in multiple processes including cell proliferation, apoptosis, cell-cycle regula- tion and ... See full document
10
Rev. Bras. Hematol. Hemoter. vol.33 número3
... available in our center only in clinical trials until 2008 when dasatinib was approved in ...European Leukemia Net group were used to define response: complete hematologic response: ... See full document
5
Transplante alogênico de células-tronco hematopoéticas em leucemias agudas: a experiência de dez anos do Hospital das Clínicas da UFMG.
... factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALL XII/ Eastern Cooperative Oncology Group (ECOG) 2993 ... See full document
8
Rev. Bras. Hematol. Hemoter. vol.35 número2
... 3. Rezende VM, Rivellis AJ, Gomes MM, Dörr FA, Novaes MM, Nardinelli L, et al. Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and ... See full document
2
Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.
... IFN-a in patients who had used the drug as monotherapy with an excellent treatment ...denominator in our patient cohort is the long lasting response to therapy, which can usually be achieved only in ... See full document
12
J. Bras. Patol. Med. Lab. vol.52 número3
... written in English, and a further 65 case ...involved in the development of endothelial and bone marrow sinusoidal ...BMN are commonly indicated by anemia, thrombocytopenia, high levels of ... See full document
7
Circulating endothelial cells in patients with venous thromboembolism and myeloproliferative neoplasms
... PE/anti-CD45 PerCP/anti-CD54 APC) was done using normal 12675 mm polypropylene tubes (BD). After incubation, red cell lysis and cell fixation were performed by adding 1 ml of pre- diluted BD FACS Lysing Solution for ... See full document
9
Clinics vol.70 número8
... 25 chronic myeloid leukemia patients who had been previously treated with imatinib and a second tyrosine kinase ...the chronic phase patients (n=18), 89% achieved a complete hematologic ... See full document
6
temas relacionados